Rodman & Renshaw Starts Sunesis Pharmaceuticals (SNSS) at Market Outperform
Tweet Send to a Friend
Rodman & Renshaw initiates coverage on Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) with a Market Outperform rating and $8 price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
